Skip to main content
. 2010 Dec;51(12):6566–6574. doi: 10.1167/iovs.10-6161

Figure 5.

Figure 5.

Effect of anti-IL-17A on ACAID and corneal allograft survival. BALB/c mice were treated with anti-IL-17A antibody or isotype control on days −4 and −2 before and twice weekly after AC injection or corneal transplantation. (A) ACAID was induced on day 0 with C57BL/6 splenic nonadherent cells. Subcutaneous injections of C57BL/6 splenocytes were given on day +7. DTH challenge with mitomycin C–treated C57BL/6 cells was on day +14. Negative control animals received an ear challenge only. ACAID groups treated with anti-IL-17A or isotype control antibody were injected in the AC with C57BL/6 antigen, SC immunized, and ear challenged with mitomycin C–treated C57BL/6 splenocytes. P > 0.05 for the anti-IL-17A–treated versus isotype control-treated group (n = 5). This experiment was performed twice with similar results. (B) C57BL/6 corneal allograft survival in BALB/c mice treated with anti-IL-17A or a rat IgG isotype control antibody. C57BL/6 corneal allografts underwent rejection in 50% of hosts treated with the isotype control IgG (n = 10) and had an MST of 46 days. C57BL/6 corneal allografts transplanted to BALB/c recipients treated with anti-IL-17A were rejected in 90% of hosts with an MST of 14.5 days (n = 10). P < 0.05 between anti-IL-17A–treated group and rat IgG isotype control treated allograft recipients. The experiment was performed four times with similar results.